Tag: PAA
PharmAust secures new lead researcher for phase IIb monepantel trial on canine lymphoma
Clinical stage oncology company PharmAust (ASX: PAA) has appointed Dr Kim Agnew as the new principal investigator for its phase IIb veterinary clinical trial testing anti-cancer drug monepantel in pet...
PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19
Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma.
During the March quarter, PharmAust...
PharmAust’s phase IIb monepantel trial identifies therapeutic window for treatment of canine lymphoma
An interim analysis of a phase IIb trial conducted by clinical-stage oncology company PharmAust (ASX: PAA) has provided supportive evidence of a therapeutic window for lead drug candidate monepantel t...
PharmAust secures $750,000 R&D refund from ATO
Clinical-stage oncology company PharmAust (ASX: PAA) has received a hefty rebate from the Australian Tax Office under the national research and development tax incentive scheme for the work of its who...
PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2
Further pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 ...
PharmAust reveals early results from phase IIb canine lymphoma trial
PharmAust (ASX: PAA) has completed assessment of the first five dogs in a phase IIb trial of its anti-cancer drug monepantel on treatment-naïve B cell lymphoma in canines, revealing only minimal side ...
PharmAust subsidiary Epichem to advance ‘world first’ waste-to-fuel conversion technology
PharmAust’s (ASX: PAA) subsidiary Epichem has inked a licencing deal that will see it research, develop and promote a disruptive flow reactor technology that converts waste to fuel.
Thermaquatica f...
PharmAust calls for more dogs for anti-cancer canine drug trial
Biotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its lead anti-cancer drug monepantel (MPL) on canine lymphoma and has put a call out for more dogs to p...
PharmAust seeks more canine participants for phase IIb lymphoma trial using lead drug monepantel
Biotechnology firm PharmAust (ASX: PAA) is looking to recruit more canines with B-cell lymphoma to a new phase IIb trial evaluating a re-formulation of its lead anti-cancer drug monepantel, which has ...
PharmAust begins next trial using monepantel to treat canines with lymphoma
Following a successful phase IIa trial using monepantel (MPL) to treat canine lymphoma, PharmAust’s (ASX: PAA) phase IIb study has begun.
The recent phase IIa trial using monepantel to treat B-cell...
PharmAust posts strong September quarter led by advances in development of lead drug monepantel
Oncology company PharmAust (ASX: PAA) has posted a strong quarter of business activity, led by a hefty grant last month for a phase 1 clinical trial to investigate the effects of lead drug monepantel ...
Olivia Newton-John Cancer Research Institute evaluates PharmAust’s anti-cancer drug
Clinical-stage oncology company PharmAust (ASX: PAA) has announced the Olivia Newton-John Cancer Research Institute (ONJCRI) is investigating the anti-cancer mechanism of its flagship drug candidate m...
PharmAust advances testing of monepantel drugs against COVID-19
PharmAust (ASX: PAA) is set to test the ability of its monepantel and monepantel sulfone drugs on their ability to inhibit coronavirus SARS-CoV-2 infection, the virus behind the COVID-19 global pandem...
PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease
Motor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a grant for a Phase 1 trial to examine the effects of its flagship drug candidate monepantel on the disea...
PharmAust lays out market strategy for lead drug monepantel
Oncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developments of its lead drug candidate, monepantel (MPL).
PharmAust is currently progressing the drug in...
PharmAust confirms monepantel’s anti-viral potential in fight against COVID-19
Determined to become one of the first companies to develop an active treatment for COVID-19, oncology company PharmAust (ASX: PAA) has reported it has successfully repeated a second round of in-vitro ...
PharmAust subsidiary Epichem signs JV to develop waste-to-fuels technology
PharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Western Australia-based private company Obsidian Minerals to develop a novel and disruptive waste-to-fuels...
PharmAust trims losses as monepantel drug development progresses
Oncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated many achievements in the overall development of its lead cancer drug, monepantel (MPL).
MPL is a vet...
PharmAust research shows monepantel can inhibit progression of SARS-CoV-2 virus
Preliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel sulfone have demonstrated that application of the drugs on human respiratory cells can inhibit the pro...
PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer
Clinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter performance to lead drug monepantel and monepantel sulfone which has shown “remarkable” early results agai...
Repeat experiment proves PharmAust’s lead cancer drug can reduce infectivity of COVID-19 cells
A repeat preliminary evaluation of PharmAust’s (ASX: PAA) lead cancer drug monepantel and monepantel sulfone has found it can reduce transmission in cells infected with the current SARS-CoV-2 strain o...
